Inhibikase Therapeutics, Inc. (IKT)

1.65 +0.06 (+3.77%) USD  |  NASDAQ  |  Dec 24, 16:00
More

Inhibikase Therapeutics EPS Diluted (5 Year Growth)

EPS Diluted (5 Year Growth) Chart

View EPS Diluted (5 Year Growth) for IKT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (5 Year Growth) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

EPS Diluted (5 Year Growth) Range, Past 5 Years

View EPS Diluted (5 Year Growth) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (5 Year Growth) Benchmarks

View EPS Diluted (5 Year Growth) Benchmarks
Start Trial
CEL-SCI Corp. Upgrade
AIM ImmunoTech, Inc. Upgrade
IGC Pharma, Inc. Upgrade
NovaBay Pharmaceuticals, Inc. Upgrade
Protalix Biotherapeutics, Inc. Upgrade